Anthem Biosciences Limited (IN:ANTHEM)
:ANTHEM
Want to see IN:ANTHEM full AI Analyst Report?
Top Page
Anthem Biosciences Limited
(ANTHEM)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹874.00
▲(15.40% Upside)
Action:N/A
Date:05/21/26
The score is driven primarily by strong financial performance (rapid growth, improving cash generation, and low leverage). Technicals are supportive with price above major moving averages and positive MACD, but the overall score is held back by a very high P/E valuation and limited visibility into the durability of FY2026’s outsized growth and cash-flow step-up.
Positive Factors
Accelerated Revenue Growth
A ~106% YoY revenue jump signals substantial contract wins or scaling of CDMO/CRD engagements, indicating stronger commercial traction and broader market acceptance. If sustained, this growth can improve operating leverage and create durable scale advantages over 2–6 months.
Negative Factors
Sustainability Risk of FY2026 Surge
An outsized single-year revenue and cash-flow step-up can reflect concentrated, timing-driven contract milestones or one-offs. Without multi-year trends, forecasting long-term earnings and capex needs is uncertain, raising the risk that margins and cash conversion may revert.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerated Revenue Growth
A ~106% YoY revenue jump signals substantial contract wins or scaling of CDMO/CRD engagements, indicating stronger commercial traction and broader market acceptance. If sustained, this growth can improve operating leverage and create durable scale advantages over 2–6 months.
Read all positive factors
Anthem Biosciences Limited (ANTHEM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹428.08B
Dividend YieldN/A
Average Volume (3M)144.08K
Price to Earnings (P/E)71.5
Beta (1Y)0.97
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees2,062
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)4.57
Shares Outstanding563,195,100
10 Day Avg. Volume43,734
30 Day Avg. Volume144,079
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)12.10
Price to Sales (P/S)17.33
P/FCF Ratio52.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹802.50Price Target Upside5.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)12.56
Revenue Forecast (FY)₹25.66B
Anthem Biosciences Limited Business Overview & Revenue Model
Company Description
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients...
How the Company Makes Money
Anthem Biosciences primarily makes money by providing outsourced services to pharmaceutical and biotechnology companies under contract-based engagements. Its main revenue streams typically include: (1) Contract Research and Development (CRD/CRO) s...
Anthem Biosciences Limited Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 10.33B | 21.24B | 18.45B |
| Gross Profit | 6.33B | 8.95B | 11.01B |
| EBITDA | 4.75B | 8.34B | 7.56B |
| Net Income | 2.56B | 5.92B | 4.51B |
Balance Sheet | |||
| Total Assets | 32.84B | 34.29B | 28.08B |
| Cash, Cash Equivalents and Short-Term Investments | 11.00B | 9.40B | 7.32B |
| Total Debt | 1.10B | 539.24M | 1.13B |
| Total Liabilities | 5.32B | 3.87B | 3.98B |
| Stockholders Equity | 27.53B | 30.43B | 24.10B |
Cash Flow | |||
| Free Cash Flow | 3.09B | 7.06B | 1.04B |
| Operating Cash Flow | 6.34B | 9.17B | 4.18B |
| Investing Cash Flow | -2.37B | -7.81B | -1.52B |
| Financing Cash Flow | -390.05M | -331.04M | -1.34B |
Anthem Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹428.08B | 71.53 | ― | ― | ― | ― | |
72 Outperform | ₹140.62B | 49.95 | ― | 0.22% | 12.35% | 14.32% | |
69 Neutral | ₹374.17B | 36.05 | ― | 2.16% | 1.93% | 11.68% | |
63 Neutral | ₹383.76B | 33.13 | ― | 0.28% | 7.91% | 54.70% | |
59 Neutral | ₹735.07B | 84.34 | ― | 0.15% | 22.67% | 147.76% | |
57 Neutral | ₹33.58B | 54.23 | ― | 0.03% | 15.15% | -7.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ANTHEM
Anthem Biosciences Limited
755.35
22.25
3.04%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,203.65
-986.86
-30.93%
IN:GUFICBIO
Gufic Biosciences Limited
347.20
-19.80
-5.40%
IN:IPCALAB
IPCA Laboratories Limited
1,495.05
73.77
5.19%
IN:LAURUSLABS
Laurus Labs Ltd.
1,388.40
778.16
127.52%
IN:RAINBOW
Rainbow Childrens Medicare Limited
1,364.80
-9.71
-0.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.